Ultragenyx Pharmaceutical Inc.

RARE

$40.16

+7.0% last 12 months

Sands Capital Holding value: $104 Million Steven Cohen Holding value: $28.8 Million Ray Dalio Holding value: $457 Thousand Ken Griffin Holding value: $56.3 Thousand Paul Tudor Jones II Holding value: $0 Baillie Gifford Holding value: $0 Ron Baron Holding value: $0 Jim Simons Holding value: $0 Joel Greenblatt Holding value: $0

Market Cap

$3.19 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$31.52 - $54.98

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-5.02x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $3.19 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $2.75 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. +7.0%
52-Week High Highest share price in the last 52 weeks. $54.98
52-Week Low Lowest share price in the last 52 weeks. $31.52
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 82.1 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 774 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -5.02
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 14.4
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$8.98
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 10.04
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company Infinity
Enterprise Value to Revenue Enterprise value divided by revenue 6.7
Enterprise Value to EBIT Enterprise Value divided by EBIT -4.64
Total Debt to Enterprise Value Total debt divided by enterprise value 0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.0

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $410 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $372 Million
EBIT Earnings before tax and interest payments. -$593 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$635 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -154.87%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -34.9%
Return on Equity Equity divided by market cap. -2003.16%
Return on Assets Indicates a company's profitability in relation to its total assets. -51.31%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -60.23%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Ultragenyx Pharmaceutical Inc.

CEO: Emil Kakkis

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Biomarin Pharmaceutical Inc. - Registered Shares
Biomarin Pharmaceutical Inc. - Registered Shares
Amicus Therapeutics Inc
Amicus Therapeutics Inc
Esperion Therapeutics Inc.
Esperion Therapeutics Inc.
Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc
Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc.

News

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Clearbridge Investments LLC

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Clearbridge Investments LLC

… by company insiders. Ultragenyx Pharmaceutical Stock Performance RARE stock opened … the current fiscal year. Ultragenyx Pharmaceutical Company Profile (Fr...

EIN News Pharmaceuticals EIN News Pharmaceuticals, 9 days ago
Profund Advisors LLC Decreases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Profund Advisors LLC Decreases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Profund Advisors LLC lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 10.0% in the second quarter, according to its most...

The AM Reporter The AM Reporter, 12 days ago
Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to “Sell” at StockNews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to “Sell” at StockNews.com

… and other institutional investors. Ultragenyx Pharmaceutical Company Profile (Get Free … Report) Ultragenyx Pharmaceutical Inc, a biopharmaceutical company...

EIN News Pharmaceuticals EIN News Pharmaceuticals, 13 days ago
Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade)

Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade)

Ultragenyx''s liquid assets and recent funding extend its cash runway, but additional financing may be needed soon. Read why I recommend RARE stock a Sell.

Seeking Alpha Seeking Alpha, 19 days ago
Never miss a trade
To improve your user experience we use cookies.